Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Trial Profile

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Bosutinib (Primary) ; Cobimetinib (Primary) ; Crizotinib (Primary) ; Dasatinib (Primary) ; Erlotinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sunitinib (Primary) ; Temsirolimus (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms CAPTUR
  • Most Recent Events

    • 09 Jan 2023 Planned End Date changed from 30 Sep 2023 to 31 Jan 2027.
    • 09 Jan 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Jan 2026.
    • 08 Nov 2022 Planned primary completion date changed from 30 Sep 2022 to 30 Jun 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top